News

EIT Urban Mobility Launches SME Market Expansion Call

Published on | 3 months ago

Programmes
Climate, Energy, Mobility EIT

The SME Market Expansion Open Call 2026 seeks to boost the market uptake of impactful innovations while mitigating development risks. With a total funding pool of €600,000, the initiative plans to support around 10 projects, each awarded €60,000. Interested small and medium enterprises (SMEs) must engage with an end-client, a public or private entity, to validate their solutions in real-world scenarios. The Call prioritises five thematic areas including Public Transport and Urban Logistics and excludes SMEs funded in the previous 2025 call.

Applications are open until 1 December 2025. For further information on the application procedure, you can visit this website

 

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1802 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.